[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656792":3},{"organization":4,"outcomesModule":7,"designInfo":32,"detailedDescription":23,"studyPopulation":23,"armGroups":39,"interventions":46,"overallOfficials":23,"centralContacts":52,"locations":61,"responsibleParty":98,"collaborators":23,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":23,"eligibilityCriteria":106,"healthyVolunteers":102,"sex":107,"minAge":108,"maxAge":23,"enrollmentInfo":109,"targetDuration":23,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":23,"overallStatus":118,"whyStopped":23,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":23},[9,13,16,18],{"measure":10,"description":11,"timeFrame":12},"Adverse events (AEs)","Safety endpoints.","From Day 1 to 40 days after last dose.",{"measure":14,"description":11,"timeFrame":15},"Dose-limiting toxicity (DLT)","From Day 1 to 12 months.",{"measure":17,"description":11,"timeFrame":15},"Maximum Tolerated Dose (MTD)",{"measure":19,"description":11,"timeFrame":15},"Recommended Phase 2 Dose (RP2D)",[21,24,26,28,30],{"measure":22,"description":23,"timeFrame":15},"Progression free survival (PFS)",null,{"measure":25,"description":23,"timeFrame":15},"Objective response rate (ORR)",{"measure":27,"description":23,"timeFrame":15},"Disease control rate (DCR)",{"measure":29,"description":23,"timeFrame":15},"Duration of response (DOR)",{"measure":31,"description":23,"timeFrame":15},"Overall survival (OS)",{"allocation":33,"interventionModel":34,"interventionModelDescription":35,"primaryPurpose":36,"observationalModel":23,"timePerspective":23,"maskingInfo":37},"NA","SINGLE_GROUP","Monotherapy.","TREATMENT",{"masking":38,"maskingDescription":23,"whoMasked":23},"NONE",[40],{"label":41,"type":42,"description":43,"interventionNames":44},"SHR-4595 Group","EXPERIMENTAL","SHR-4595 for Injection, in different stages with different doses.",[45],"Drug: SHR-4595 for Injection",[47],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":23},"DRUG","SHR-4595 for Injection","SHR-4595 for injection, in different doses.",[41],[53,58],{"name":54,"role":55,"phone":56,"phoneExt":23,"email":57},"Hongxia Han","CONTACT","+86-0518-82342973","hongxia.han@hengrui.com",{"name":59,"role":55,"phone":56,"phoneExt":23,"email":60},"Yuanchao Wang","yuanchao.wang@hengrui.com",[62,82],{"facility":63,"status":23,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute)","Shenyang","Liaoning","110042","China","CN",{"type":70,"coordinates":71},"Point",[72,73],123.43278,41.79222,{"lat":73,"lon":72},[76,80],{"name":77,"role":55,"phone":78,"phoneExt":23,"email":79},"Yefu Liu","+86-024-88619613","LZLyf1111@163.com",{"name":77,"role":81,"phone":23,"phoneExt":23,"email":23},"PRINCIPAL_INVESTIGATOR",{"facility":83,"status":23,"city":84,"state":85,"zip":86,"country":67,"countryCode":68,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Tianjin Cancer Hospital","Tianjin","Tianjin Municipality","300060",{"type":70,"coordinates":88},[89,90],117.17667,39.14222,{"lat":90,"lon":89},[93,97],{"name":94,"role":55,"phone":95,"phoneExt":23,"email":96},"Jihui Hao","+86-022-23340123","haojihui@tjmuch.com",{"name":94,"role":81,"phone":23,"phoneExt":23,"email":23},{"type":99,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100656792","phase-1-a-clinical-study-of-shr-4595-injection-in-patients-with-advanced-solid-tumors-to-evaluate-safety-tolerability-and-pharmacokinetics-100656792",false,"NCT07830199","A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics","An Open-label, Multicenter Phase I Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics","Inclusion Criteria:\n\nA subject must satisfy all of the following criteria to be considered for inclusion in the study.\n\n1. The subjects voluntarily joined the study and signed the ICF.\n2. Measurable disease, as defined by RECIST v1.1.\n3. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.\n4. Life expectancy ≥ 12 weeks.\n5. Subjects with cytologically or histologically confirmed advanced solid tumors who have failed or are intolerant to standard therapy, have no standard therapy, or refuse standard therapy.\n\nExclusion Criteria:\n\nA subject who meets any of the following criteria will be excluded from study entry.\n\n1. Symptomatic, untreated or active central nervous system metastases.\n2. Have uncontrolled or severe cardiovascular disease Have clinical symptoms or disease of the heart that are not well controlled.\n3. With any active autoimmune disease or history of autoimmune disease.\n4. Patients with active hepatitis B or hepatitis C.\n5. Severe infections prior to initiation of study treatment.","ALL","18 Years",{"count":110,"type":111},208,"ESTIMATED","INTERVENTIONAL",[114],"PHASE1","The study is being conducted to evaluate the safety and tolerability of SHR-4595 for injection in participants with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose for Phase II clinical studies (RP2D) of SHR-4595.",[117],"Solid Tumor","NOT_YET_RECRUITING","2026-09-15",{"date":121,"type":122},"2026-09-21","ACTUAL",{"date":124,"type":111},"2026-09",{"date":126,"type":111},"2030-12",{"name":5,"class":6},2]